In a bold bet on the future of longevity, top-tier venture firm Kleiner Perkins has led a $130 million Series A funding round in NewLimit, the antiaging biotech startup founded by Coinbase co-founder Brian Armstrong. The round signals growing investor confidence in the emerging field of cellular reprogramming, a next-gen scientific approach that aims to reverse aging at its root.
As seen in Millionaire MNL, NewLimit’s mission to radically extend human healthspan is no longer just a moonshot. With elite backing and a team of top scientists, the company is positioning itself at the frontier of biotech innovation—merging AI, genomics, and regenerative medicine to rewrite what it means to grow old.
From crypto to cellular reprogramming
Brian Armstrong, best known for launching Coinbase into a crypto giant, co-founded NewLimit in 2021 with Blake Byers, a former general partner at Google Ventures and a bioengineering PhD. Their vision: to use epigenetic reprogramming to reverse age-related cellular decline and extend the number of healthy, disease-free years in human life.
“Most biotech focuses on treating individual diseases,” Armstrong said in a recent interview. “We’re trying to understand and reset the underlying code of aging itself.”
NewLimit isn’t trying to achieve immortality, he emphasized, but to delay the onset of diseases like Alzheimer’s, cardiovascular decline, and immune dysfunction that often accompany aging.
What NewLimit actually does
NewLimit focuses on epigenetics, the molecular mechanisms that regulate which genes are turned on or off in a cell. Over time, these controls degrade, leading to cellular aging and dysfunction. By using machine learning and CRISPR-based tools to reprogram gene expression, NewLimit aims to “reset” aged cells back to a more youthful state—without turning them into stem cells or causing uncontrolled growth.
While the science is still early-stage, recent breakthroughs in cellular reprogramming from labs like Harvard’s and Altos Labs have shown that partial reprogramming can rejuvenate tissues in mice and even restore vision in aging animals.
NewLimit’s core belief: if you can slow or reverse aging at the cellular level, you can dramatically extend human healthspan—keeping people biologically younger for longer.
The $130 million Series A: who’s backing the bet?
Led by Kleiner Perkins, a storied name in venture capital with early investments in Amazon, Google, and Genentech, the round also includes backing from Founders Fund, Dimension, and several biotech-focused angels. Armstrong and Byers also contributed significant personal capital.
The funding will be used to expand NewLimit’s lab capabilities, hire leading scientists in genomics, machine learning, and cell biology, and accelerate its internal platform for identifying epigenetic targets that influence aging.
As seen in Millionaire MNL, this is more than just a cash infusion—it’s a stamp of validation from Silicon Valley’s most forward-thinking investors that longevity science is the next frontier of disruptive innovation.
“We believe aging will be one of the most important medical frontiers of the next 20 years,” said Ilya Fushman, partner at Kleiner Perkins. “NewLimit is building a world-class team to lead that charge.”
Silicon Valley’s new obsession: antiaging
NewLimit joins a growing list of well-funded longevity startups backed by tech elite, including Altos Labs (reportedly backed by Jeff Bezos), Calico (from Google parent Alphabet), and Retro Biosciences. The influx of capital signals a belief that aging is not just a fact of life—it’s a solvable engineering problem.
What sets NewLimit apart, according to insiders, is its tight integration of AI, genomics, and high-throughput screening. Rather than taking a pharma-style approach of discovering one drug at a time, NewLimit is building a scalable platform to rapidly test reprogramming factors and identify those with the greatest potential to restore function in aging cells.
While the field is still in its infancy and clinical applications remain years away, early in-vitro results have been promising. The company has not yet published peer-reviewed data but says publications are forthcoming in late 2024.
Ethical stakes and future outlook
As longevity tech gains momentum, it also invites serious ethical questions. Who will have access to age-reversing treatments? Will longer life exacerbate inequality? Could cellular reprogramming have unintended consequences?
Armstrong and Byers say they’re approaching the science with caution, emphasizing that their goal is not luxury life extension for the elite, but scalable interventions that could be used as widely as vaccines or statins.
Their long-term goal: add 10–20 healthy years to the average human life, not just for the wealthy, but eventually for the world.
NewLimit’s Series A round is a milestone not just for the company, but for the broader longevity movement—turning the promise of age reversal from science fiction into a plausible near-future reality.
